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Abstract 
We discuss the etiology and pathogenesis of Parkinson's disease (PD). Our group and others have found a decrease in complex I of the 
mitochondrial electron transfer complex in the substantia nigra of patients with PD; in addition, we reported loss of the a-ketoglutarate 
dehydrogenase complex (KGDHC) in the substantia nigra. Dual loss of complex I and the KGDHC will deleteriously affect the electron 
transport and ATP synthesis; we believe that energy crisis is the most important mechanism of nigral cell death in PD. Oxidative stress 
has also been implicated as an important contributor to nigral cell death in PD, but we believe that oxidative stress is a secondary 
phenomenon to respiratory failure, because respiratory failure will increase oxygen free-radical formation and consume glutathione. The 
primary cause of mitochondrial respiratory failure has not been elucidated yet, but additive effect of environmental neurotoxins in 
genetically predisposed persons appears to be the most likely possibility. 
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1. Introduction 
Parkinson's disease (PD) is a disease of middle to 
elderly age characterized clinically by resting tremor, rigid- 
ity, akinesia, and postural disturbance; its prevalence varies 
from a country to another, and the disease is more frequent 
among Western countries than Asian and African countries 
[1-3]. Pathologically PD is characterized by degeneration 
of the substantia nigra and the locus coeruleus, and appear- 
ance of Lewy bodies in the neuronal cytoplasm. As the 
substantia nigra sends dopaminergic fibers to the striatum, 
dopamine content and the tyrosine hydroxylase activity of 
the striatum are drastically decreased [4-6]. 
As the primary cause of PD has not been elucidated yet, 
numbers of hypotheses have been postulated which include 
mitochondrial theory, iron accumulation theory, free radi- 
cal theory, neurotoxin theory, and genetic predisposition 
theory. These theories are not mutually exclusive; more 
than two of these mechanisms may play a role together. 
Mitochondrial hypothesis was born after the discovery of 
MPTP ( 1 -methyl-4-phenyl- 1,2,3,6-tetrahydropyridine). We 
will briefly review the mechanism of nigral cell death in 
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MPTP-induced Parkinsonism, and then discuss the etiol- 
ogy of PD. 
2. Mitochondria in MPTP-induced Parkinsonism 
MPTP was found as a contaminant of illicit narcotics in 
the United States [7,8]. People who injected narcotic drugs 
contaminated by MPTP developed severe Parkinsonism 
[7-9]. MPTP is oxidized to MPP + (l-methyl-4-phenyl- 
pyridinium ion) by monoamine oxidase B [10] (Fig. 1), 
and this MPP-- is the actual substance which is toxic to 
nigral cells [11,12]. As monoamine oxidase B is mainly 
expressed in glia cells and serotonergic neurons [13,14], 
this oxidation of MPTP probably takes place mainly in glia 
cells. Nigrostriatal dopaminergic neurons contain 
monoamine oxidase A [15]. MPP ÷ is taken up actively 
through the dopamine transporter, and is accumulated 
within nigrostriatal dopaminergic neurons [12,16-18]. 
We were interested in the mechanism of MPP+-induced 
neuronal death; we noted a structural similarity between 
MPP ÷ and NAD ÷ (Fig. 1), and we thought MPP ÷ might 
inhibit NAD-linked mitochondrial respiratory enzymes; we 
found dose-dependent i hibition of the complex I activity 
by MPP + using mouse brain mitochondria s an enzyme 
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Fig. 1. Structure of MPTP, oxidation of MPTP by monoamine oxidase B, 
MPP +, and similarity between MPP + and NAD +. 
source [19-22]. Shortly before our publication, Nicklas et 
al. [23] found inhibition of state 3 respiration supported by 
NAD+-linked substrates, and Ramsay et al. [24] found 
inhibition of mitochondrial NADH dehydrogenase. The 
question was a fact that mM order of MPP + was necessary 
to inhibit complex I when freeze-thawed mitochondrial 
preparation was used, but only /xM order of MPP + was 
Table 1 
Effect of MPP + on mitochondrial respiration, complex I activity, and 
ATP synthesis 
Control MPP ÷ 
State 3 a 180±25 21±4 * 
State 4 a 30±5 11 +_3 * 
Complex I b 57± 13 27+_6 * 
ATP formed 637 +_ 23 210 +_ 31 * 
Mean±S.E. ,  n = 9. * : P < 0.001, g lutamate+malate as substrates, 
MPP + = 50 /xM. 
a (nAtom O/ ra in  per mg prot,) 
b (nmol NADH ox id ized/min  per mg prot.) 
c (nmol ATP formed from 750 nmol ADP), cited from Ref. [22]. 
Table 2 
Effect of MPP + on dehydrogenases in the TCA cycle 
Dehydrogenase Control MPP + 
Isocitrate DH 285 + 37 266 + 35 
Glutamate DH 556 + 50 545 ___ 52 
a-Ketoglutarate DHC 34 + 5 19 + 3 * 
Malate DH 4760 + 530 4870 _+ 690 
Units: nmol NADH formed/min  per mg prot.; mean _+ S.E., n = 8. *" 
P < 0.001, MPP + = 2 raM, cited from Ref. [22]. 
suffice to inhibit state 3 respiration of intact mitochondria. 
This question was soon resolved by the discovery of active 
transport of MPP + into mitochondria [25,26] and 40-fold 
concentration within them [26]. 
To explicitly prove that complex I inhibition is the 
cause of mitochondrial respiratory failure in MPP+-toxic - 
ity, we measured the complex I activity using intact mito- 
chondria which had been incubated with /zM order of 
MPP + together with NAD+-linked substrates and ADP; as 
shown in Table 1, 50 /xM MPP + was suffice to obtain 
50% inhibition of complex I in this condition [20,22]. In 
addition, the cerebral complex I activity was decreased in
mice treated with MPTP subcutaneously [28]. Furthermore, 
we noted that the magnitude of inhibition of state 3 
respiration was far greater than that of the complex I (88% 
vs. 53%, Table 1). We thought here might be another 
enzyme that would be inhibited by MPP ÷, and thus we 
found inhibition of the a-ketoglutarate dehydrogenase 
complex (KGDHC) of mitochondria by MPP ÷ ([27], Table 
2); the magnitude of inhibition was in the same order as 
that of complex I. Therefore, in this model, inhibitions of 
complex I as well as the KGDHC play an important role in 
the respiratory failure and energy crisis. 
3. Mitochondria in PD 
3.1. Electron transfer complexes in PD brains 
Schapira et al. [29,30] first reported a significant reduc- 
tion in the complex I activity in the substantia nigra of 
patients with PD; this decrease was not found in other 
disorders which affected the substantia nigra such as multi- 
ple system degeneration [31]. Reichmann et al. [32] also 
reported a slight but significant decrease in NADH-cyto- 
chrome c reductase in the substantia nigra, but in their 
second series of subjects, they could not detect loss of 
complex I activity. We also measured activity of complex I 
in the striatum in a small number of patients died of PD 
[33], however, the decrease in complex I activity did not 
reach the statistical significance. Therefore, we studied the 
amount of complex I protein by Western blotting [34] and 
immunohistochemistry [35]. In Western blotting, the lower 
Table 3 
Potential causes of mitochondrial respiratory failure 
Cause 
Mitochondrial DNA deletions 
Mitochondrial DNA mutations or polymorphisms 
Mutations or polymorphisms of nuclear DNA coding subunits of complex I 
Mutations or polymorphisms of nuclear DNA coding enzymes regulating the transport and metabolism of potential nigral neurotoxins 
Endogenous or exogenous nigral neurotoxins 
Localized accelerated ageing 
Oxidative stress 
Secondary to neurodegeneration 
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Table 4 
Complex I activity in tissues other than the brain in PD 
267 
Author PD (n) Control (n) Reference 
Muscle 
Bindoff et al. 132.4 _+ 39.9 * * (5) 222.0 + 29.5 
Shoffner et al. 16-174 # (6) 197 + 50 
Nakagawa-Hattori et al. 64.10 + 21.30 * * (4) 125.1 + 13.7 
Mann et al. 62.4 _+ 7.8 (9) 63.2 _+ 1.9 
Anderson et al. 14 ± 2 (4) 16 _+ 2 
DiDonato et al. 11.6 _+ 3.4 #~ (6) 11.0 ± 2.9 
Cardellach et al. 245.8 + 42.8 * * (8) 331.6 + 60.1 
Platelet 
Parker et al. 8.7 +__ 2.9 * * * (10) 19.1 _ 5.6 
Yoshino et al. 9.14 _+ 1.86 * ~ * (20) 12.37 _ 2.66 
Mann et al. 3.51 _+ 0.79 (14) 3.53 _+ 0.72 
Krige et al. 8.26 _+ 1.34 * * (25) 9.88 _+ 2.14 
Lymphocyte 
Yoshino et al. 10.10 _ 2.93 (20) 11.11 + 1.18 
(4) [36] 
(16) [38] 
(6) [40] 
(6) [41] 
(5) [42] 
(6) ## [43] 
(10) [44] 
(8) [45] 
(17) [46] 
(9) [41] 
(15) [47] 
(17) [46] 
Units: nmol /min per mg prot.; mean + S.E. * * P < 0.01, * * * P < 0.001. #: Four out of 6 patients below the 5% confidence level for the control 
subjects, ##: Expressed as % nmol of substrate/min per mg prot. normalized to citrate synthase. PD: Parkinson's disease. 
molecular mass subunits (20 to 30 kDa) of complex I was 
reduced in 4 out of 5 patients with PD in the striatum. In 
immunohistochemistry, he intensity of immunostaining of
the substantia nigra was semiquantitatively analyzed, and 
we counted those neurons showing marked reduction in 
immunostaining [35]. In controls subjects, 13.6+4.2% 
(mean + S.D., n = 6) of nigral neurons showed marked 
reduction in immunostaining for complex I; interestingly, 
there was a positive correlation between the age of the 
patients and the loss of immunoreactivity to complex I. In 
PD patients, significantly higher proportions of neurons 
(35.6___ 17.6%, n = 8) showed marked reduction in im- 
munostaining (P  < 0.01), 
Thus there is no question about the loss of neuronal 
complex I in PD, but it is unlikely that this loss is the 
primary and a genetically determined defect, as the loss of 
complex I was rather modest both biochemically [29,30] 
and immunohistochemically [35]. Potential causes of com- 
plex I deficiencies in PD are listed in Table 3; all of those 
possibilities have to be studied extensively to elucidate the 
pathogenesis of PD. It seems unlikely that the loss of 
complex I is a mere reflection of neuronal degeneration, as
other electron transfer complexes were normal [29,30,35]. 
3.2. Complex I in tissues other than brain 
Regarding the complex I in tissues other than the brain, 
some controversies exist in the literature [36-47]. As 
shown in Table 4, most of the studies showed slight but 
significant decreases in complex I activity in skeletal 
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Fig. 2. Schematic representation showing the relationship between the c~-ketoglutarate dehydrogenase complex in the TCA cycle and the electron transfer 
complex. The KGDHC provides not only NADH for complex I but also succinate for complex II. PDHC, pyruvate dehydrogenase complex; CS, citrate 
synthase; ICDH, isocitrate dehydrogenase; GDH, glutamate dehydrogenase; KGDHC, oz-ketoglutarate d hydrogenase complex; SDH, succinate dehydro- 
genase; MDH, malate dehydrogenase; CI, complex I; CII, complex II; CIII, complex III; CIV, complex IV; Cyt. C, cytochrome c. 
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muscles and platelets. The question is whether they repre- 
sent mere by chance observations or they reflects the 
underlying pathologic process of PD. Suppose environ- 
mental neurotoxins and/or genetic predisposition are in- 
volved in PD, they may present a modest abnormality in 
platelets and the skeletal muscle, as platelets do not have a 
nucleus and the skeletal muscles are largely composed of 
post-mitotic ells; both of them are not expected to have 
ample compensatory mechanisms to eliminate noxious 
stimuli imposed upon them. Therefore, marginal abnormal- 
ities may appear in those tissues, and we cannot dismiss 
those abnormalities. As the substantia nigra has a unique 
property to augment he effect of those noxious stimuli 
such as the dopamine transporter, neuromelanin, and high 
iron and dopamine contents, more severe damage may be 
induced. 
3.3. c~-Ketoglutarate dehydrogenase complex in PD 
As we [27] found inhibition of the KGDHC by MPP +, 
we thought his enzyme complex might also be impaired in 
PD. The KGDHC, consisting of c~-ketoglutarate d car- 
boxylase, dihydrolipoamide succinyltransferase, and dihy- 
drolipoamide dehydrogenase, is located between ~-keto- 
glutarate and succinate in the TCA cycle; the overall 
reaction oxidizes a-ketoglutarate o succinate which be- 
comes the substrate of complex II (Fig. 2). Therefore, the 
KGDHC is a very important enzyme; when complex I is 
decreased, electron transfer will shift toward the complex 
II to complex III pathway; for the effective lectron trans- 
fer through this pathway, supply of succinate is mandatory. 
In addition, it has been claimed that the KGDHC is the 
rate-regulating enzyme of the TCA cycle [48]. 
We wanted to measure the enzymatic activity of this 
enzyme on autopsy-obtained brain tissue [33], but we 
could not recover the biochemical activity in autopsy-ob- 
tained brain tissue apparently due to unstableness of this 
enzyme; acidosis in the agonal stage was reported to 
influence the enzyme activity significantly [49]. Therefore, 
we adopted an immunohistochemical method [50]. The 
specific antibody was kindly supplied by Dr. Matuda of 
Kanoya University of Sports and Fitness. We studied 6 
control subjects and 9 Parkinsonian patients; the details 
were published elsewhere [50]. In the control subjects, the 
substantia nigra showed uniform immunostaining for the 
KGDHC; the lateral part of the substantia nigra showed 
somewhat weaker immunostaining. The lateral part is most 
extensively involved in PD; the reason for this vulnerabil- 
ity of the lateral part is not known, however, it may in part 
be related to this medial to lateral gradient in the amount 
of this enzyme complex. We counted the number of neu- 
rons showing marked reduction in immunostaining for the 
KGDHC in the substantia nigra. In control patients, only 
elderly subjects had a small number of neurons showing 
marked reduction in the immunostaining, however, in PD, 
there was a marked increase in the proportion of those 
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Fig. 3. Semiquantitative analysis of immunohistochemistry for the 
KGDHC. The upper graphs represent PD patients, and the lower graphs 
control subjects; each number corresponds to the case number; the 
ordinate represents percentages of nigral neurons howing marked reduc- 
tion in the immunostaining for the KGDHC in respective r gions of the 
substantia nigra; 'medial' denotes the medial one-third of the substantia 
nigra, and 'lateral' the lateral one-third of the substantia nigra. 
neurons howing marked reduction in the immunostaining 
(Fig. 3); this increase was particularly prominent in the 
lateral part of the substantia nigra. There was a rough 
correlation between the loss of immunoreactivity and the 
severity of degenerative changes. 
Dual loss of complex I and the KGDHC will severely 
impair the electron transfer. The KGDHC appear to be 
another vulnerable nzyme complex of mitochondria; other 
NAD-linked dehydrogenases (glutamate dehydrogenase, 
isocitrate dehydrogenase, and malate dehydrogenase) in 
the TCA cycle were not decreased in PD in our previous 
study [33]. The KGDHC was reported to be inhibited by 
pathological concentrations of ammonia (0.2-2 mM) and 
by calcium at concentrations above 100 /zM [51]; there- 
fore, decrease in the urea cycle activity and accumulation 
of calcium ion from any cause would have a deleterious 
effect on the KGDHC. Recently, Mastrogiacomo etal. [49] 
reported a significant decrease in the cortical KGDHC 
activity in Alzheimer's disease; this may be another evi- 
dence to indicate the vulnerability of this enzyme complex. 
Interestingly, complex I and the KGDHC are located in 
close proximity each other within mitochondria [52]. 
3.4. Mitochondrial DNA in PD 
As complex I is composed of 41 subunits [53] and 7 out 
of those 41 subunits are encoded by mtDNA [54,55], we 
wanted to study mtDNA for mutations in PD. First of all, 
we looked at the so-called common 5 kb deletion of 
mtDNA by the PCR method. This 5 kb deletion occurs 
between the 13-base pair direct repeat sequence [56] en- 
compassing enes for ND 5, ND 4, ND 4L, ND 3, CO 3, 
and ATPase 6/8. Therefore, deletion in this part would 
cause loss of complex I. Ikebe et al. [57] studied striatal 
mtDNA of 5 patients died of PD; in all the PD patients 
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studied, the 5 kb common deletion was found; in addition 
2 elderly control subjects above 70 years of age also 
harbored the same deletion. However, the amount of dele- 
tion was rather small, less than 5% of striatal mitochon- 
drial DNA [58]. This may be the reason why mtDNA 
deletion could not be detected by the Southern blotting 
method in other laboratories [59,60]. Since then, many 
reports appeared confirming the presence of the 5 kb 
common deletion in PD brains [43,61,62], but they de- 
tected the same deletion in the age-matched control sub- 
jects, and the deletion was ascribed to the ageing process. 
Mann et al. [62] quantitated the amount of mtDNA dele- 
tion in PD and control subjects, and found that the both 
groups showed same amount of the deletion (4.1 + 0.6%); 
DiDonato et al. [43] also quantitated the percentage of the 
common deletion in brain areas, and that approx. 3% of 
mtDNA was deleted in the substantia nigra in both control 
and PD subjects. 
The common 5 kb deletion was also found in tissues 
other than the brain; Sandy et al. [63] found the 5 kb 
deletion in platelets of both PD and control subjects, and 
we found the same deletion in the skeletal muscle; al- 
though the same deletion was found also in control sub- 
jects, the deletion appeared to be seen in earlier ages in 
PD, in that, a 52 year-old control subject did not have this 
deletion, but 61 year-old control person had the deletion; 
in PD patients, this deletion was seen in patients at age 53 
or above in our condition (Fig. 4). However, as ageing-as- 
sociated mtDNA deletions have frequently been reported 
not only in brains [64-67] but also in cardiac muscles 
[67-70], skeletal muscles [67,71,72], and the liver [73], 
mtDNA deletions found in PD may not have an etiologic 
significance. MtDNA deletion in ageing itself is an inter- 
esting observation. 
Regarding mtDNA sequence, Shoffner et al. [74] re- 
ported higher incidence of PD patients carrying A to G 
mutation at nucleotide pair 4336 of the mitochondrial gene 
Cont ro l  P D 
i I r 1 
1 2 3 4 5 6 7 8 9 10 
':b 
for tRNA g~n (5.3% in PD vs. 0.7% in their controls); we 
are also studying mtDNA sequence in PD, however, we 
could not detect a point mutation common to PD patients. 
4. Oxidative stress in PD 
4.1. Free radicals and glutathione in PD 
Marttila et al. [75] reported 55% increase in the Cu-Zn 
SOD activity and Saggu et al. [76] 33% increase in the Mn 
SOD in the PD substantia nigra. These results were inter- 
preted as indicating increased formation of superoxide 
anions. Increase in the lipid peroxidation was also reported 
[77]. These represent earlier reports suggesting the pres- 
ence of oxidative stress in PD. 
Another evidence for oxidative stress came from the 
observation on iron in PD. There are many papers report- 
ing increase in iron content in the substantia nigra of PD 
patients compared with the controls [78-84]. Ferrous iron 
may interact with hydrogen peroxide to produce hydroxyl 
radicals [85]. Thus, iron may be toxic to neurons; Tanaka 
et al. [86,87] reported that iron could be toxic to cultured 
neurons as well. We also showed toxicity of iron using 
nigral and striatal co-culture [88]; this co-culture simulates 
the in vivo state better than mesencephalic culture alone, 
as it includes target cells and striatal trophic factors; 
arborization of neural processes is much better than the 
mesencephalic culture alone, being suitable for the study 
of potential neurotoxins. Co-administration of synthetic 
neuromelanin and iron markedly inhibited the development 
of dendritic processes with neuronal degeneration and 
increase in the lipid peroxidation [88]. However, we be- 
lieve that iron increase in PD is secondary to neuronal 
degeneration, as iron was also increased in the substantia 
nigra of MPTP-treated monkeys [89]. 
Another interesting observation which suggests the 
presence of oxidative stress in PD is reduced level of GSH 
(glutathione) in the substantia nigra [79,90-93]. GSH is a 
substrate for glutathione peroxidase which not only decom- 
poses hydrogen peroxide and lipid peroxides but also 
protects cell membranes from oxidative damage together 
with glutathione peroxidase [94,95]. 
4.2. Relationship between mitochondrial respirator), fail- 
ure and oxidative stress 
20 52 61 72 80 50 53 67 76 77 (y) 
Fig. 4. PCR analysis of skeletal muscle mtDNA for the so-called common 
5 kb deletion in control subjects and PD patients; the numbers in each 
lane represent the age of the subjects; the 52 year-old control subject does 
not have the deletion, but the 61 year-old control person had the deletion; 
in PD patients, this deletion is seen in patients at age 53 or above. 
Recently, Jenner et al. [92] postulated that complex I
deficiency might be secondary to oxidative stress; this 
notion is based on the observation on GSH and complex I 
in incidental Lewy body disease where Lewy bodies are 
discovered incidentally in patients who died without clini- 
cal as well as biochemical evidence of PD; the condition 
may represent preclinical stage of PD [96]. GSH was 
reported to be significantly decreased whereas complex I
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was marginally diminished in incidental Lewy body dis- 
ease [92,93]; this appears to be the reason why they 
thought complex I deficiency was secondary to oxidative 
stress. 
Although oxidative stress hypothesis i very attractive, 
it is difficult to consider that the oxidative stress is the 
primary event. First of all, GSH is synthesized in astro- 
cytes [97-100], and only a small amount is contained in 
neurons if any [97,98,100,101]. Mitochondrial GSH is 
transported from the cytoplasm through the high affinity 
transporter [102]. Suppose the oxidative stress is the pri- 
mary event in PD, loss of GSH would suggest hat the 
disease starts in nigral astrocytes, but neurons are mainly 
involved in PD. Secondary, not only complex I but also 
the KGDHC is reduced in PD; therefore, impairment of 
mitochondrial respiration would more severe than what 
would be expected from complex I deficiency alone. 
Furthermore, there is a good reason to believe that 
mitochondrial respiratory failure will induce oxidative 
stress. Production of hydrogen peroxide [103,104] and 
superoxide anions [105,106] were shown in normal mito- 
chondria; the site of superoxide anion production was 
ascribed to ubiquinol and ubisemiquinone [107,108]. Fur- 
thermore, when complex I or III is inhibited, formation of 
superoxide anions is markedly augmented [109-112]. Hy- 
droxyl radicals are also formed within mitochondria [113]. 
Hydroxyl radicals are very cytotoxic including oxidative 
DNA damage [85]; in fact, Hayakawa et al. [114,115] 
reported age associated oxidative damage in cardiac mus- 
cles and accumulation of 8-hydroxydeoxy-guanosine, a  
indicator of oxidative DNA damage [116], in human di- 
aphragm. Thus mitochondrial respiratory failure will in- 
duce oxidative stress within mitochondria. In addition, 
normally high content of dopamine and iron [ 117] predis- 
poses the substantia nigra to oxidative stress. 
Oxidative stress within mitochondria will consume GSH. 
When reduced level of mitochondrial GSH is associated 
with increase in activated oxygen species, mitochondrial 
calcium homeostasis will be disrupted, in that pores in the 
inner membrane will open resulting in release of Ca 2+ and 
influx of cytoplasmic omponents [118]. In fact, swelling 
of mitochondria occurs in experimentally induced GSH 
deficient rats [119]. ATP deficiency also causes welling of 
mitochondria [120]; therefore, mitochondrial swelling in 
GSH deficient rats may be the result of ATP deficiency. 
ATP deficiency will increase cytoplasmic Ca 2+, and in- 
crease in Ca 2+ will initiate protean adverse reactions in 
neurons including apoptosis [121]. Respiratory failure and 
oxidative stress will induce a vicious cycle, in that, oxida- 
tive stress in turn compromises electron transport further; 
hydroxyl radicals are known to attack NADH dehydro- 
genase, ATPase and succinate dehydrogenase, and super- 
oxide anions inhibit the activities of NADH dehydrogenase 
and ATPase [122]; the reason for these vulnerability is 
thought o be due to the fact that cardiolipin, which is an 
essential cofactor for those enzymes, is rich in unsaturated 
fatty acid and is liable to be attacked by oxygen free 
radicals [123]. 
5. Etiology of PD 
5.1. Potential nigral neurotoxins 
PD may be caused by neurotoxins which accumulate 
selectively within nigral neurons and inhibits complex I
like MPP +, Based on this hypothesis, numbers of endoge- 
nous and exogenous compounds have been tested for 
nigral or mitochondrial toxicity. Thus tetrahydroisoquino- 
lines (TIQ) were studied first. As shown in Fig. 5, tetrahy- 
HCHO 
C" "°; Oq..  \ ,  CO,. 
Pheflylalanine Phen)'lethylamine TI.~_Q 
PH ,~ NMT 
Tyrosine N-Me-TIQ N-Me-lsoquinolinium ion 
,~TH HCHO 
H H 
HO" ~ NH2 
DOPA Dopamine Norsalsolinol 
~ NMT ~'" 
"CH3 
N-Me-Norsalsolinol N-Me-Norsalsolinium ion 
Fig. 5. Formation of tetrahydroisoquinoline a d salsolinol from phenylethylamine and dopamine, respectively. Tetrahydroisoquinolines are further 
N-methylated and oxidized to quinolinium ions by monoamine oxidase or by auto-oxidation. PH, phenylalanine hydroxylase; TH, tyrosine hydroxylase; 
AAD, aromatic L-amino acid decarboxylase; NMT, N-methyltransferase; MAO, monoamine oxidase; TIQ, tetrahydroisoquinoline. 
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droisoquinolines have structural similarity to MPP +, and 
numbers of derivatives are known. In addition, some of 
them are formed endogenously from phenylethylamine 
[ 124,125] or from catecholamines [ 126,127], and found in 
human brains [124-127]; furthermore they exist in some of 
natural plants and foods such as cheese, cocoa, banana, 
milk, egg and beef [128,129]. In addition, transport of TIQ 
from foods to the brain was shown in monkeys [130]. 
Another interesting observation is that 1-methyl derivative 
of T1Q was found decreased in the striatum of PD patients 
[131], and it prevented MPTP-induced Parkinsonism in 
mice [132]; thus less toxic substances may be neuroprotec- 
tive against more toxic compounds, and this observation 
may have a therapeutic mplication in future. 
Yoshida et al. [133] treated monkeys with a large 
amount of tetrahydroisoquinoline, and those monkeys 
showed clinical manifestations similar to Parkinsonism and 
decrease in dopamine, tyrosine hydroxylase and biopterine 
in the nigrostriatal regions [134]. Mice treated with TIQ 
showed a marked decrease in tyrosine hydroxylase-posi- 
tive neurons in the substantia nigra, however, cell death 
did not occur [135]. In an effort to find a more toxic 
substance, Naoi et al. [ 136,137] found N-methylation reac- 
tion of TIQ, and oxidation reaction of N-methyl-TIQ to 
N-methylisoquinolinium ion(NMIQ+); this oxidized com- 
pound was found more toxic than the parent compound 
inhibiting tyrosine hydroxylase, aromatic L-amino acid de- 
carboxylase and monoamine oxidase [138]. In addition, 
NMIQ + was found toxic to cultured mesencephalic 
dopaminergic neurons [139,140], and to the nigral neurons 
of mice treated with N-methyl TIQ [141]. Furthermore, 
TIQs inhibit mitochondrial respiration and complex I 
[142,143], but the potency to inhibit state 3 respiration is 
much weaker than that of MPP +. 
Naoi and his associates also studied dopamine derived 
TIQs [144-147], i.e., salsolinol and its derivatives (Fig. 4); 
salsolinol was found to inhibit tyrosine hydroxylase [145], 
to stimulate release of monoamines with inhibition of 
monoamine oxidase and catechol-O-methyltransferase 
[146]; melanin was found to bind N-methylsalsolinium ion 
[1471. 
Another interesting roup of substance includes fi- 
carbolines, derivatives of tryptamine, which have been 
shown to be toxic to catecholaminergic neurons [148,149]; 
they exist in human brains [ 150,151 ], inhibit mitochondrial 
respiration [ 152], bioactivated by monoamine oxidase [ 153], 
and inhibit dopamine uptake into the catecholaminergic 
neurons [154]. Thus both TIQs and fl-carbolines represent 
candidates for the etiologic agent of PD. 
5.2. Ent:ironmental f ctors 
Connection between rural living and well water drink- 
ing and PD [155-157], and connection between pesticide 
and herbicide exposure [158-164] as well as industrial 
exposures to chemicals, heavy metals [159,165] and PD 
have been reported; however, some studies could not find 
connection between PD and well water drinking [166] or 
herbicides exposure [156,166]. Recently, Fleming et al. 
[167] reported presence of diedline (an organic mercury 
compound) in 6 of 20 PD brains, but none in the control 
subjects; but they reserved the conclusion regarding 
whether or not diedline is an etiologic agent for PD. 
Kondo and Watanabe [168] reported deficiencies in the 
intake of protein, carbohydrates, fruits, and dairy products 
prior to the secondary growth period as a possible contrib- 
utor to the pathogenesis of PD. Therefore, there is no 
question about he role of certain environmental exposures 
in the development of PD, but its exact chemical nature 
awaits further investigations. 
5.3. Genetic predisposition 
Genetic difference in the activities of enzymes which 
regulate the transport and metabolism of potential neuro- 
toxins may also play a role in the pathogenesis of PD. 
In this respect, Armstrong et al. [169] and Smith et al. 
[170] found higher incidence of the genetic defects which 
would result in debrisoquine poor metabolizers among 
patients with PD; Smith et al. [171] found a higher inci- 
dence of G-to-A transition at the junction of intron 3/exon 
4 and 1 bp deletion mutation at the exon 5 of CYP2D6 
gene in PD; both of those mutations render the subjects 
poor metabolizers for debrisoquine, and the incidence of 
poor metabolizers was 11.8% in PD and 5.0% in the 
control subjects. 
Kurth et al. [171 ] found higher frequency of allele 1 of 
the gene for monoamine oxidase B (62% in PD vs. 45% in 
their controls). Hotamisligil et al. [172] reported a signifi- 
cant difference in the alleles frequencies of MAO A and 
MAO B between PD and the controls, in that, one particu- 
lar baplotype marked by the RFLPs at MAO A was three 
times more frequent in PD patients (14%) compared with 
controls (5%), and the distribution of MAO A alleles 
defined by the RFLPs was significantly different (P  < 
0.03); for MAO B alleles defined by the (GT) n repeat, the 
incidence of allele 180 was almost wice as common in PD 
patients (21%) as controls (12%), and the overall distribu- 
tion of alleles was significantly different between patients 
with PD and controls. 
In summary, PD may be initiated by nigral neurotoxins 
in the environment in genetically susceptible persons; more 
than two genetic predispositions may be necessary to be 
afflicted with PD. 
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